Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 15 de 15
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Vox Sang ; 106(1): 38-44, 2014 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-23888911

RESUMO

BACKGROUND AND OBJECTIVES: Buffy-coat (BC)-derived platelet concentrates (PCs) are the predominant product for platelet transfusion in many countries. Two automated systems, OrbiSac and TACSI, have been introduced in blood centres to prepare these PCs, as an alternative to the manual method. We compared the in vitro quality of PCs prepared by both methods during standard storage. STUDY DESIGN AND METHODS: Twenty primary BC pools were split into two parts, which were processed with OrbiSac and TACSI system to obtain OrbiSac PCs (O-PCs) and TACSI PCs (T-PCs), respectively. On days 1, 5 and 7 of standard storage, samples were taken and the following analysed: cell count, metabolic variables, platelet function and content of activation and proinflammatory substances. RESULTS: Both the OrbiSac and TACSI systems produced PCs that meet the standards for platelet products in terms of platelet and leucocyte content. In vitro evaluation pointed to the similar preservation of platelet metabolism (pH, glucose, bicarbonate and lactate) in O-PCs and T-PCs. Moreover, there were no significant differences between O-PCs and T-PCs as regards the hypotonic shock response or in the platelet aggregation profile. The OrbiSac system caused greater platelet activation, which resulted in higher concentrations of sCD62P, RANTES and sCD40L on the day the PCs were prepared. CONCLUSION: The systems OrbiSac and TACSI can be used to produce buffy-coat-derived PCs whose cell content, platelet function and metabolism are similar during standard storage. However, the preparation with the OrbiSac system induces a transient increase in platelet activation and release of proinflammatory substances.


Assuntos
Buffy Coat/citologia , Plaquetas/citologia , Plasma/citologia , Plaquetoferese/instrumentação , Buffy Coat/fisiologia , Plaquetas/fisiologia , Humanos , Procedimentos de Redução de Leucócitos , Plasma/química , Ativação Plaquetária , Agregação Plaquetária , Testes de Função Plaquetária , Transfusão de Plaquetas
2.
Rev Enferm ; 35(4): 28-34, 2012 Apr.
Artigo em Espanhol | MEDLINE | ID: mdl-22745997

RESUMO

Oral anticoagulant therapy (OAT) with Vitamin K antagonists requires frequent analytical controls that create a certain degree of dependency and a loss of autonomy in the patient. These drugs have an undesirable variability due to food and drug interactions, febrile processes, etc. which can modify the patient's INR and predispose them to a thromboembolic or hemorrhagic event. OAT self-control is supported by more than 15 years of experience in countries such as Germany and the Netherlands, and by comparative studies that reflect a reduction of thromboembolism and other adverse effects. The reason of this is because these patients are in the correct therapeutic range for longer periods of time due to more frequent controls (once a week against every 4-5 weeks of traditional control) and also to a better understanding of their treatment. In Aragon, OAT is a free health service and in our hospital, OAT has been an institutional aim since 2070. After a training course, the patient is capable to make their own INR determinations at home, to evaluate their results and adjust their own dose. Additionally the patient should acquire the appropriate knowledge to detect any adverse symptom and to know how to react to any problem in their treatment. This article summarizes our experience regarding the implementation of the programme and creation of the specific unit: the organization and training of the professionals involved, establishment of the patient selection criteria, and design of the patients' training course, follow-up strategy and equipment. In addition, the results of the study conducted in our Unit, showing a high degree of patient satisfaction, are included. At this moment 20% of our patients are included in the self-control strategy.


Assuntos
Anticoagulantes/administração & dosagem , Educação de Pacientes como Assunto , Administração Oral , Humanos , Desenvolvimento de Programas , Autoadministração
3.
Oncogene ; 38(28): 5739, 2019 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-31053808

RESUMO

The original microRNA hybridization data for this article, which has been available for the scientific community upon request, has now been deposited in the GEO repository under accession number GSE124432.

4.
Hum Pathol ; 11(1): 51-7, 1980 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-7364439

RESUMO

Liver lesions in 17 patients with serologically diagnosed Q fever are described. A distinctive granulomatous pattern, with granuloma formation plus a fibrinoid ring, was observed in 14 cases. In two cases the fibrinoid material consisted of fibrillar eosinophilic structures without an annular arrangement, interspersed among epithelioid cells. In only one case was a nonspecific granuloma (devoid of fibrinoid material) noted. We conclude that the association of a granuloma with fibrinoid material is highly indicative of Q fever, but serial sections are often necessary to demonstrate this pattern.


Assuntos
Granuloma/patologia , Hepatite/etiologia , Febre Q/complicações , Adulto , Idoso , Biópsia por Agulha , Diagnóstico Diferencial , Fibrina , Granuloma/diagnóstico , Granuloma/etiologia , Hepatite/patologia , Humanos , Fígado/patologia , Masculino , Pessoa de Meia-Idade , Febre Q/patologia
5.
Am J Clin Pathol ; 98(6): 598-602, 1992 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-1334365

RESUMO

Adenomyoepithelioma of the breast is a rare tumor that, on the basis of histologic, immunohistochemical, and ultrastructural features, has a bicellular pattern of epithelial and myoepithelial cells regularly distributed in tubular structures. Until now, this tumor was thought to be a benign or low-grade malignant lesion because of possible local recurrences (7 recurrent cases of 60 in the literature). Only one of these cases had nodal involvement, thereby suggesting the possible malignancy of this lesion. This paper reports the first documented case of malignant adenomyoepithelioma with lung metastases presenting the same biphasic pattern as the primary tumor.


Assuntos
Neoplasias da Mama/patologia , Carcinoma Adenoide Cístico/patologia , Carcinoma Adenoide Cístico/secundário , Feminino , Humanos , Imuno-Histoquímica , Neoplasias Pulmonares/patologia , Neoplasias Pulmonares/secundário , Microscopia Eletrônica , Pessoa de Meia-Idade
6.
Prog Urol ; 2(6): 1045-59, 1992 Dec.
Artigo em Francês | MEDLINE | ID: mdl-1302128

RESUMO

The usual histological techniques are necessary and sufficient for the routine diagnosis of bladder tumours. Many laboratory tools are designed to determine prognostic factors but require such technical conditions that they cannot be used routinely. The determination of DNA ploidy by flow cytometry of voided urine, fresh, formalin-fixed or paraffin-embedded tumour fragments is a simple, standardised and reproducible technique and the method of choice of pathologists as it allows morphological control of the element analysed. Based on a series of 720 bladder tumours collected by 3 different centres, the authors demonstrate how to use, correlate and integrate into routine practice the data of image analysis flow cytometry in relation to conventional cytology and histology. 5% of grade 1 tumours, 27% of grade 2 tumours, and 92% of grade 3 tumours were DNA aneuploid. 17% of non-invasive tumours (PTa) and 79% of invasive tumours (PT1 and more) were DNA aneuploid. These proportions are in line with the results of various series in the literature. DNA ploidy is therefore an objective and measurable element completing histological grading. The determination of DNA ploidy also helps the cytologist in difficult cases of urine cytology.


Assuntos
Neoplasias da Bexiga Urinária/patologia , DNA de Neoplasias/análise , Humanos , Ploidias , Prognóstico , Neoplasias da Bexiga Urinária/química
7.
Oncogene ; 33(23): 3054-63, 2014 Jun 05.
Artigo em Inglês | MEDLINE | ID: mdl-23851508

RESUMO

Matrix metalloproteinases (MMPs) have been traditionally implicated in cancer progression because of their ability to degrade the extracellular matrix. However, some members of the MMP family have recently been identified as proteases with antitumor properties. Thus, it has been described that collagenase-2 (MMP-8) has a protective role in tumor and metastasis progression, but the molecular mechanisms underlying these effects are unknown. We show herein that Mmp8 expression causes a decrease in miR-21 levels that in turn leads to a reduction in tumor growth and lung metastasis formation by MDA-MB-231 (4175) breast cancer cells. By using both in vitro and in vivo models, we demonstrate that the mechanism responsible for these MMP-8 beneficial effects involves cleavage of decorin by MMP-8 and a subsequent reduction of transforming growth factor ß (TGF-ß) signaling that controls miR-21 levels. In addition, miR-21 downregulation induced by MMP-8 increases the levels of tumor suppressors such as programmed cell death 4, which may also contribute to the decrease in tumor formation and metastasis of breast cancer cells overexpressing this metalloproteinase. These findings reveal a new signaling pathway for cancer regulation controlled by MMP-8, and contribute to clarify the molecular mechanisms by which tumor-defying proteases may exert their protective function in cancer and metastasis.


Assuntos
Neoplasias da Mama/metabolismo , Decorina/metabolismo , Neoplasias Pulmonares/metabolismo , Neoplasias Pulmonares/secundário , Metaloproteinase 8 da Matriz/metabolismo , MicroRNAs/metabolismo , Animais , Neoplasias da Mama/genética , Linhagem Celular Tumoral , Feminino , Regulação Neoplásica da Expressão Gênica , Humanos , Neoplasias Pulmonares/patologia , Camundongos , Camundongos Nus , Metástase Neoplásica , RNA Interferente Pequeno/farmacologia , Transdução de Sinais , Ensaios Antitumorais Modelo de Xenoenxerto
8.
Semergen ; 39(6): 313-5, 2013 Sep.
Artigo em Espanhol | MEDLINE | ID: mdl-24034759

RESUMO

Quaternary prevention has been commonly defined with the "primum non nocere" of classical texts by many authors. The daily life of our primary care consultations are full of patients in which we wondered if we try to obtain the benefit of our intervention will exceed the damage we cause him to intervene. Patients with multiple comorbidities, polypharmacy and complex are common in our consultations and it is becoming more difficult to move the balance of our actions, diagnostic or therapeutic benefit to the side. Through 2 cases often move to the reflection of this problem. Quaternary prevention must also be present in our daily activities.


Assuntos
Antagonistas de Androgênios/efeitos adversos , Anilidas/efeitos adversos , Conservadores da Densidade Óssea/efeitos adversos , Ciproterona/efeitos adversos , Prescrição Inadequada/prevenção & controle , Indóis/efeitos adversos , Nitrilas/efeitos adversos , Osteoporose/tratamento farmacológico , Atenção Primária à Saúde , Neoplasias da Próstata/tratamento farmacológico , Compostos de Tosil/efeitos adversos , Idoso de 80 Anos ou mais , Feminino , Humanos , Masculino
9.
Eur J Cancer ; 49(9): 2126-33, 2013 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-23473612

RESUMO

BACKGROUND: The detection of KRAS mutations is mandatory to initiate an anti-epidermal growth factor receptor (EGFR) antibody in the treatment of metastatic colorectal carcinoma (mCRC). PATIENTS AND METHODS: This observational retrospective study was performed in 160 French centres during a 2-week period in 2011. Its main objective was to evaluate the rate of KRAS testing in patients with mCRC having initiated their first-line therapy. Secondary objectives included time of process, techniques used and reasons for non-prescription. RESULTS: Five hundred and thirty eight mCRC patients (67.1 ± 11.3 years, synchronous metastases: 69.9%) were enrolled in the study. KRAS testing was prescribed in 81.1% of patients, in a median of 15 days after the diagnosis of metastases, and of 15 days prior to the initiation of the first-line metastatic chemotherapy. KRAS status was available for 87% of patients, after 23.6 ± 28.2 days, but after the choice of the first-line therapy in 56.6% of patients. Heterogeneity of reception time was noteworthy within regions (8.3 ± 7 days to 38.8 ± 101 days). KRAS testing was not prescribed mainly due to the planned non-prescription of an anti-EGFR antibody. CONCLUSION: This study confirmed that KRAS testing is definitely part of the management of most of mCRC patients, despite discrepancies observed in the rate of prescription and the time of results.


Assuntos
Neoplasias do Colo/genética , Genes ras/genética , Mutação/genética , Neoplasias Retais/genética , Adulto , Idoso , Antineoplásicos/uso terapêutico , Neoplasias do Colo/tratamento farmacológico , Análise Mutacional de DNA/estatística & dados numéricos , Receptores ErbB/antagonistas & inibidores , Feminino , França , Testes Genéticos/estatística & dados numéricos , Genótipo , Humanos , Masculino , Pessoa de Meia-Idade , Metástase Neoplásica , Padrões de Prática Médica/estatística & dados numéricos , Neoplasias Retais/tratamento farmacológico , Encaminhamento e Consulta/estatística & dados numéricos , Estudos Retrospectivos , Fatores de Tempo
14.
Cancer ; 44(3): 1009-13, 1979 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-476585

RESUMO

This investigation was carried out on 100 bone marrow biopsies with metastases and 56 autopsies on patients with evidence of cancer. Leukoerythroblastosis was found in 44% of the patients with bone marrow mestastases and was more frequent in prostatic and gastric carcinoma. Moreover, the postmortem study of patients who died with cancer showed that leukoerythroblastosis was always the sign of bone marrow metastasis. A significant correlation was found between these blood changes and bone marrow fibrosis around the metastasis. Furthermore, leukoerythroblastosis seems caused by hepatosplenic extra medullary hematopoiesis.


Assuntos
Anemia Mielopática/complicações , Neoplasias/complicações , Anemia Mielopática/patologia , Medula Óssea/patologia , Feminino , Hematopoese , Humanos , Fígado/patologia , Masculino , Metástase Neoplásica , Neoplasias/sangue , Neoplasias/patologia , Prognóstico , Baço/patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA